Preliminary study of two antiviral agents for hepatitis C genotype 1.
By A. Lok, David F. Gardiner, E. Lawitz, C. Martorell, G. Everson, R. Ghalib, R. Reindollar, V. Rustgi, F. Mcphee, M. Wind-Rotolo and 7 more. New England Journal of Medicine, 2012
638 citations recorded by the source corpus.
Subfields: Hematology, Hepatology, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/c933db7a56f554e56ad3be302dbc5d41b0af7a5f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- A Quantitative High-Resolution Genetic Profile Rapidly Identifies Sequence Determinants of Hepatitis C Viral Fitness and Drug Sensitivity (2014, methodology): “The pharmacokinetic parameters are set to reflect the current recommended drug regimen for Daclatasvir, 60 mg once daily [58,59].”